Parabolic Drugs Ltd. announced audited standalone earnings results for the fourth quarter and year ended March 31, 2016 and consolidated earnings results for the year ended March 31, 2016. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 132.3 million against INR 266.1 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 950.8 million against INR 923.3 million a year ago. Loss from ordinary activities before tax was INR 1,234.1 million against INR 1,352.2 million a year ago. Net loss was INR 1,278.4 million or INR 20.66 per basic and diluted share before & after extraordinary items against INR 2,885.9 million or INR 46.63 per basic and diluted share before & after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 742.2 million against INR 2,287.8 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 3,731.4 million against INR 1,503.1 million a year ago. Loss from ordinary activities before tax was INR 4,807.6 million against INR 2,490.0 million a year ago. Net loss was INR 4,851.9 million or INR 78.40 per basic and diluted share before & after extraordinary items against INR 3,793.2 million or INR 61.29 per basic and diluted share before & after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 754.6 million against INR 2,291.5 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 3,736.4 million against INR 1,511.6 million a year ago. Loss from ordinary activities before tax was INR 4,812.7 million against INR 2,501.5 million a year ago. Net loss was INR 4,857 million or INR 78.48 per basic and diluted share before & after extraordinary items against INR 3,804.7 million or INR 61.48 per basic and diluted share before & after extraordinary items a year ago.